Search
- Oct 16
Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy
Josh Cohen and Justin Klee on the negative opinion, what it means for ALS patients in Europe, and a new statistical analysis of CENTAUR.
- Aug 15
Catching up with the co-founders of Amylyx on the launch of their ALS treatment
Josh Cohen and Justin Klee discuss the launch of RELYVRIO, the PHOENIX P3 trial, and reflect on the roller coaster of the last year.
